Start Your Search
P1.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session) (ID 949)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
P1.17-05 - Accelerated Radiotherapy for Non-Small Cell Lung Cancer: A 12 Year Retrospective Review of Two Dose Fractionation Schedules (ID 13818)
16:45 - 18:00 | Author(s): Bilal Tahir
Numerous dose fractionation regimes have been used for inoperable NSCLC patients and there is evidence that accelerated schedules can produce better outcome than conventionally fractionated treatment (1). Continuous hyperfractionated accelerated radiotherapy (CHART, 54Gy in 36 fractions over 12 days) and accelerated hypofractionated radiotherapy (55Gy in 20 fractions over 4 weeks) have been routinely used in Sheffield over the past decade, with schedule selection largely down to patient choice (in-patient vs out-patient treatment). In this single-centre retrospective analysis, we present the outcomes for all patients treated with these two schedules between 2003 to 2015.
1. LePechoux C, Mauguen A, Baumann M, et al. Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis. JCO 2012;30:2788-2797.a9ded1e5ce5d75814730bb4caaf49419 Method
In this audit details on patient demographics, tumour characteristics and survival data was collected from the electronic hospital records and supplemented by information from patient notes. Dosimetric data for tumour and organs at risk were collated automatically via the Varian Eclipse Scripting application programming interface. Descriptive statistical analysis was performed using the SSPS package with clinical and dosimetric variables assessed using independent samples t-tests and survival via a log-rank test. Multivariate survival analysis was performed using Cox regression.4c3880bb027f159e801041b1021e88e8 Result
We identified 883 eligible patients, of which 45% received CHART and 55% hypofractionated radiotherapy. Mean age was 70 years and 58% were male. PET staging was performed in 87% with 30%, 15%, 51% and 4% being stage I, II, III and IV, respectively. 63% had a WHO performance status of 0-1. 38% of patients underwent induction chemotherapy. 99% completed their prescribed radiotherapy treatment with an overall response rate of 60%. Relapse was observed in 50% of patients with median disease-free survival of 19.4 months. 2-year overall survival was 47% with a median overall survival of 23.2 months. Multivariate analysis identified histology, stage, performance status, use of chemotherapy as independent predictors of survival. No significant differences between the two radiotherapy regimes was seen for any parameters.8eea62084ca7e541d918e823422bd82e Conclusion
This audit has confirmed that both CHART and hypofractionated accelerated radiotherapy are deliverable and well tolerated schedules when used in day to day practice. We have detected no significant difference in outcome between the two schedules and there is the need to explore avenues, eg dose escalation, that develop these schedules to match outcomes reported by recent concurrent chemo-radiation studies.6f8b794f3246b0c1e1780bb4d4d5dc53
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.